Turner Cortney A, Akil Huda, Watson Stanley J, Evans Simon J
Department of Psychiatry, Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.
Biol Psychiatry. 2006 Jun 15;59(12):1128-35. doi: 10.1016/j.biopsych.2006.02.026. Epub 2006 May 2.
Recent evidence now suggests the involvement of the fibroblast growth factor (FGF) system in mood disorders. Specifically, several members of the FGF family have been shown to be dysregulated in individuals with major depression. In this review, we will introduce the FGF system in terms of structure and function during development, in adulthood, and in various regions and cell types. We will also review the FGF system as a mediator of neural plasticity. Furthermore, this review will summarize animal as well as human studies. The majority of animal studies have focused on stress, environmental enrichment, pharmacological manipulations, and the hippocampus. By contrast, human studies have focused on volumetric measurements, antidepressant literature, and, most recently, post-mortem microarray experiments. In summary, a reduced tone in the FGF system might alter brain development or remodeling and result in a predisposition or vulnerability to mood disorders, including major depression.
最近有证据表明，成纤维细胞生长因子（FGF）系统与情绪障碍有关。具体而言，FGF家族的几个成员在重度抑郁症患者中显示出失调。在本综述中，我们将从发育过程、成年期以及不同区域和细胞类型的角度介绍FGF系统的结构和功能。我们还将综述FGF系统作为神经可塑性介质的情况。此外，本综述将总结动物研究和人体研究。大多数动物研究集中在应激、环境富集、药物操作和海马体上。相比之下，人体研究集中在体积测量、抗抑郁文献以及最近的死后微阵列实验上。总之，FGF系统活性降低可能会改变大脑发育或重塑，并导致易患情绪障碍，包括重度抑郁症。
